• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Benzamycin (erythromycin 3%-benzoyl peroxide 5% topical gel)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Benzamycin (erythromycin 3%-benzoyl peroxide 5% topical gel)

  • Profile

Profile

Contact Information

Contact: Bausch Health
Website: https://www.bauschhealth.com/Portals/25/Pdf/PI/Benzamycin-PI.pdf

Currently Enrolling Trials

    Show More

    General Information

    Benzamycin is a combination of two active ingredients, benzoyl peroxide and erythromycin, which has proven effective in stopping acne-causing bacteria and reducing acne infection. 

    Benzamycin is specifically indicated for the topical treatment of acne vulgaris.

    Benzamycin is supplied as a gel for topical administration. The gel should be applied twice daily, morning and evening, or as directed by a physician, to affected areas after the skin is thoroughly washed, rinsed with warm water and gently patted dry.

    Mechanism of Action

    Benzamycin is a combination of two active ingredients, benzoyl peroxide and erythromycin, which has proven effective in stopping acne-causing bacteria and reducing acne infection. Erythromycin is an antibiotic produced from a strain of Saccharopolyspora erythraea, whereas benzoyl peroxide is an antibacterial and keratolytic agent (causes the break down of keratin).

    Side Effects

    Adverse effects associated with the use of Benzamycin Topical Gel may include, but are not limited to, the following:

    • Dryness
    • Urticarial reaction (hives, itching)
    • Peeling
    • Burning sensation
    • Inflammation of the face, eyes, and nose
    • Skin discoloration
    • Oiliness
    • Tenderness of the skin

    Clinical Trial Results

    No clinical trial data is available on company site or drug label.

    Approval Date: 2000-11-01
    Company Name: Bausch Health
    Back to Listings

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing